Your session is about to expire
← Back to Search
Other
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 365 days
Summary
This trial tests a new drug called AMG 890 in people with high levels of Lipoprotein(a), which is linked to heart disease. The study will check if the drug is safe and how well people tolerate it. Researchers will also see how the drug moves through the body and its effect on Lipoprotein(a) levels. AMG 890 is currently being tested for its effectiveness in reducing lipoprotein(a) levels.
Eligible Conditions
- Cardiovascular Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 365 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 365 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in PR interval
Changes in QRS interval
Changes in QT interval
+15 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AMG 890Experimental Treatment1 Intervention
Single Ascending Dose Cohorts
Group II: PlaceboPlacebo Group1 Intervention
Single Ascending Dose Cohorts
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 890
2018
Completed Phase 1
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
AmgenLead Sponsor
1,442 Previous Clinical Trials
1,397,665 Total Patients Enrolled
MDStudy DirectorAmgen
980 Previous Clinical Trials
941,421 Total Patients Enrolled